Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS Reports First Quarter 2026 Results
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison
SOPHiA GENETICS Q4 Earnings Call Highlights
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
Comparing SOPHiA GENETICS (NASDAQ:SOPH) & Precipio (NASDAQ:PRPO)
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
1,409,160 Shares in SOPHiA GENETICS SA $SOPH Bought by Alta Wealth Advisors LLC
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
Analyzing MSP Recovery (NASDAQ:MSPR) & SOPHiA GENETICS (NASDAQ:SOPH)
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
SOPHiA GENETICS (NASDAQ:SOPH) Trading 2.8% Higher – What’s Next?
Comparing SOPHiA GENETICS (NASDAQ:SOPH) and Azenta (NASDAQ:AZTA)
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025
A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology
SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript
SOPHiA GENETICS Reports Second Quarter 2025 Results
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025
SOPHiA GENETICS SA (NASDAQ:SOPH) Shares Sold by Squarepoint Ops LLC
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
SOPHiA GENETICS Reports First Quarter 2025 Results
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025